liu Jianmin

Sinovac Biotech Co., Ltd., Haiding, 100193, Beijing, China
Author    Correspondence author
International Journal of Clinical Case Reports, 2024, Vol. 14, No. 5   
Received: 03 Jul., 2024    Accepted: 10 Aug., 2024    Published: 06 Sep., 2024

This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This study evaluates the efficacy of cancer vaccines in clinical trials, focusing on their impact on overall survival (OS), progression-free survival (PFS), and tumor response rates. The study synthesizes data from various studies, including vaccines for different cancer types such as non-small cell lung cancer, melanoma, and breast cancer. Results indicate that while cancer vaccines can generate immune responses, their ability to consistently improve clinical outcomes varies depending on factors like patient characteristics, tumor type, and combination with other therapies such as immune checkpoint inhibitors. In many trials, combination therapies demonstrated superior efficacy compared to vaccines alone, suggesting that vaccines may be most effective when used as part of a multimodal approach. The study also highlights challenges such as limited response rates in some cancers, the need for better biomarkers, and optimization of vaccine delivery systems. Overall, cancer vaccines offer promise, but further research is necessary to enhance their clinical impact.

Cancer vaccines; Immunotherapy; Clinical trials; Tumor response; Combination therapies